World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
43372
World Ranking
9528
National Ranking
4912

Overview

David F. Penson is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily focuses on medicine, with a strong concentration in pulmonary and respiratory medicine, economics and econometrics, surgery, oncology, and general health professions. The main areas of their work include prostate cancer treatment and research, prostate cancer diagnosis and treatment, health systems with economic evaluations and quality of life, economic and financial impacts of cancer, bladder and urothelial cancer treatments, patient-provider communication in healthcare, and cancer-related lipids and metabolism.

Frequent publication venues for David F. Penson include:

  • The Journal of Urology
  • Prostate Cancer and Prostatic Diseases
  • Journal of Clinical Oncology
  • Urologic Oncology Seminars and Original Investigations
  • Urology

David F. Penson has collaborated extensively with several co-authors, notably:

  • Daniel A. Barocas
  • Tatsuki Koyama
  • Li-Ching Huang
  • Zhiguo Zhao
  • Karen E. Hoffman

Their recent publications reflect contributions to significant topics within prostate cancer and oncology. Notable recent papers include:

  • NCCN Guidelines Insights: Prostate Cancer, Version 1.2021 (2021), published in the Journal of the National Comprehensive Cancer Network
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer (2020), published in New England Journal of Medicine
  • Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer (2020), published in JAMA
  • Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020), published in Prostate Cancer and Prostatic Diseases
  • Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease (2022), published in Nature Communications

Best Publications

  • Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

    Philip W. Kantoff;Celestia S. Higano;Neal D. Shore;E. Roy Berger

  • Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia

    Kevin T. McVary;Claus G. Roehrborn;Andrew L. Avins;Michael J. Barry

  • Early detection of prostate cancer: AUA Guideline

    H. Ballentine Carter;Peter C. Albertsen;Michael J. Barry;Ruth Etzioni

  • Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

    Ruth Etzioni;David F. Penson;Julie M. Legler;Dante di Tommaso

  • Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    James L. Mohler;Emmanuel S. Antonarakis;Andrew J. Armstrong;Anthony V. D'Amico

  • Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer

    Matthew J. Resnick;Tatsuki Koyama;Kang-Hsien Fan;Peter C. Albertsen

  • Epidemiology and cost of ventral hernia repair: making the case for hernia research

    B. K. Poulose;J. Shelton;S. Phillips;D. Moore

  • Overdiagnosis and Overtreatment of Prostate Cancer

    Stacy Loeb;Marc A. Bjurlin;Joseph Nicholson;Teuvo L. Tammela

  • Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study

    Arnold L. Potosky;William W. Davis;Richard M. Hoffman;Janet L. Stanford

  • Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them

    Paul L. Nguyen;Shabbir M.H. Alibhai;Shehzad Basaria;Anthony V. D’Amico

  • Prostate Cancer, Version 1.2016

    James L. Mohler;Andrew J. Armstrong;Robert R. Bahnson;Anthony Victor D'Amico

  • 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study.

    David F. Penson;Dale McLerran;Ziding Feng;Lin Li

  • Nationwide Trends in Mastectomy for Early-Stage Breast Cancer

    Kristy L. Kummerow;Kristy L. Kummerow;Liping Du;David F. Penson;David F. Penson;Yu Shyr

  • Quantifying the role of PSA screening in the US prostate cancer mortality decline

    Ruth Etzioni;Alex Tsodikov;Alex Tsodikov;Angela Mariotto;Aniko Szabo;Aniko Szabo

  • Prostate Cancer and the Will Rogers Phenomenon

    Peter C. Albertsen;James A. Hanley;George H. Barrows;David F. Penson

  • Prostate cancer, version 1.2021: Featured updates to the nccn guidelines

    Edward Schaeffer;Sandy Srinivas;Emmanuel S. Antonarakis;Andrew J. Armstrong

  • Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years

    Daniel A. Barocas;Jo Ann Alvarez;Matthew J. Resnick;Tatsuki Koyama

  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

    Cora N. Sternberg;Karim Fizazi;Fred Saad;Neal D. Shore

  • Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

    David F. Penson;Andrew J. Armstrong;Raoul Concepcion;Neeraj Agarwal

  • Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

    M.P.H. Steven B. Zeliadt Ph.D.;M.P.H. Steven B. Zeliadt Ph.D.;Scott D. Ramsey M.D.;Scott D. Ramsey M.D.;M.P.H. David F. Penson M.D.;M.P.H. Ingrid J. Hall Ph.D.

Frequent Co-Authors

Ann S. Hamilton
Ann S. Hamilton University of Southern California
Sam S. Chang
Sam S. Chang Vanderbilt University Medical Center
Matthew R. Cooperberg
Matthew R. Cooperberg University of California, San Francisco
Peter C. Albertsen
Peter C. Albertsen University of Connecticut Health Center
Michael S. Cookson
Michael S. Cookson University of Oklahoma
Joseph A. Smith
Joseph A. Smith Vanderbilt University Medical Center
Janet L. Stanford
Janet L. Stanford Fred Hutchinson Cancer Research Center
Sheldon Greenfield
Sheldon Greenfield University of California, Irvine
Scott D. Ramsey
Scott D. Ramsey Fred Hutchinson Cancer Research Center
Mark S. Litwin
Mark S. Litwin University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or supplementary education in healthcare can broaden your career options beyond traditional medical degrees. Many students are drawn to advanced online programs offering flexibility and accelerated timelines. For example, dnp programs online provide an accessible route for nurses seeking terminal degrees, combining rigorous coursework with remote learning convenience.

Some professionals look for less intensive pathways, such as enrolling in a dnp program without clinical hours, to skip in-person requirements and complete credentials faster. Those beginning their careers in nursing may consider fast track lpn programs online to quickly enter the workforce and gain essential hands-on experience.

Additionally, for those interested in mental health, the shortest post master's pmhnp online programs allow experienced nurses to specialize in psychiatric care efficiently via distance learning. Exploring these related pathways can open doors to specialized or advanced practice roles outside of the traditional medical doctor route.

Best Scientists Citing David F. Penson

Trending Scientists

Recently Published Articles